When researching the imprint G 32, it is critical to note that pill visual identifiers can vary depending on manufacturer markings, exact color variations, and additional letters.
The most common primary prescription identification for “M G 32” or “G 32” in a white tablet format corresponds to Glipizide and Metformin Hydrochloride 2.5 mg / 500 mg (manufactured by Mylan/Viatris).
- (Note: If your tablet is light-orange with “G 32” printed on one side, it is Naproxen 250 mg, 375 mg, or 500 mg manufactured by Glenmark Pharmaceuticals. This article focuses on the white oral tablet Glipizide and Metformin Hydrochloride 2.5 mg / 500 mg, as well as providing context for the Glenmark Naproxen variant.)
Physical Identification
Characteristic | Primary Identification (White Tablet) | Alternative Identification (Light-Orange Tablet)
- Active Ingredients Glipizide (2.5 mg) + Metformin HCl (500 mg) Naproxen (250 mg, 375 mg, or 500 mg)
- Imprint M G 32 G 32 (with 250, 375, or 500 on the reverse)
- Color & Shape White, Oval / Capsule-shaped | Light Orange, Round or Oval
- Drug Class Antidiabetic Combination (Sulfonylurea + Biguanide) Nonsteroidal Anti-Inflammatory Drug (NSAID)
- Primary Manufacturer Mylan Pharmaceuticals Glenmark Pharmaceuticals
Mechanism of Action
The Glipizide / Metformin 2.5 mg / 500 mg combination tablet works via two complementary antidiabetic mechanisms to regulate blood glucose in adults with Type 2 Diabetes Mellitus:
- Glipizide (Sulfonylurea): Stimulates the beta cells of the pancreas to secrete endogenous insulin. It lowers acute blood sugar levels by boosting postprandial (after-meal) insulin secretion.
- Metformin Hydrochloride (Biguanide): Works primarily in the liver and peripheral tissue:
- Decreases hepatic glucose production (gluconeogenesis).
- Decreases intestinal absorption of glucose.
- Improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Dosage & Administration
Dosing must be individualized based on effectiveness, tolerance, and current blood sugar control.
Standard Administration
- With Meals: This medication must be taken with meals to minimize gastrointestinal discomfort caused by metformin and to reduce the risk of hypoglycemia caused by glipizide.
- Starting Dosage: For patients whose type 2 diabetes is not adequately controlled with diet and exercise alone, the starting dose is usually 2.5 mg / 250 mg or 2.5 mg / 500 mg once daily with a meal.
- Titration: Dosage increments should be made slowly (every 1 to 2 weeks) based on blood glucose readings.
- Maximum Dose: The maximum recommended daily dose is 20 mg glipizide / 2000 mg metformin per day (typically divided twice daily with breakfast and dinner).
Side Effects
Common Side Effects
- Gastrointestinal Disturbances: Diarrhea, nausea, vomiting, abdominal bloating, gas, and stomach upset (mostly due to the metformin component; typically subsides over time).
- Hypoglycemia (Low Blood Sugar): Dizziness, shakiness, sweating, rapid heartbeat, confusion, or headache (caused by the glipizide component).
- Headache or Metallic Taste in the mouth.
Serious Side Effects
Seek immediate emergency medical attention if you experience:
- Lactic Acidosis: A rare but potentially fatal buildup of lactic acid caused by metformin. Symptoms include severe fatigue, muscle pain, trouble breathing, unexplained stomach discomfort, feeling cold, and slow or irregular heartbeat.
- Severe Hypoglycemia: Loss of consciousness or seizures due to dangerously low blood sugar.
- Allergic Reactions: Hives, skin rash, or swelling of the face, lips, tongue, or throat.
Boxed Warnings & Key Precautions
FDA Black Box Warning: Risk of Lactic Acidosis
Metformin carries a prominent warning regarding Lactic Acidosis:
- The risk increases significantly in patients with severe renal impairment, liver disease, congestive heart failure, acute dehydration, heavy alcohol consumption, or during surgical procedures involving contrast dyes.
Key Precautions & Contraindications
- Renal Function: Contraindicated in patients with severe kidney impairment .
- Metabolic Acidosis: Do not use if you have acute or chronic metabolic acidosis, including diabetic ketoacidosis (DKA).
- Iodinated Contrast Dyes: Therapy should be temporarily discontinued prior to or at the time of radiological imaging procedures using iodinated contrast material in patients with reduced kidney function.
- Alcohol Consumption: Excessive alcohol intake (acute or chronic) potentiates the risk of both severe hypoglycemia and lactic acidosis.
Major Drug Interactions
Medication / Substance Interaction Effect
- Alcohol Increases risk of lactic acidosis and severe hypoglycemia.
- Beta-Blockers (e.g., metoprolol, atenolol) May mask early warning signs of low blood sugar (e.g., tremors, racing heart).
- Diuretics & Corticosteroids Tend to elevate blood glucose, opposing the antidiabetic effect.
- Carbonic Anhydrase Inhibitors (e.g., topiramate) May increase the risk of lactic acidosis.